Your session is about to expire
← Back to Search
Genomically Directed Monotherapy for Breast Cancer
Study Summary
This trial will test if personalized therapy for each individual's tumor will be more effective than the current standard of care.
- Breast Cancer
Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2022 Phase 2 trial • 193 Patients • NCT02101385Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- You don't have any serious infections, as decided by your doctor.
- Group 1: Arm A (Genomically Directed Monotherapy)
- Group 2: Control Arm B (Observation/Standard Therapy)
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Are there still opportunities for individuals to join this experiment?
"Clinicaltrials.gov reveals that this experiment is not actively recruiting right now, though it was initially posted on April 3rd 2014 and last updated on August 30th 2022. Nevertheless, over 4 thousand other clinical trials are looking for participants currently."
Does the FDA recognize Genomically Directed Monotherapy as a viable treatment option?
"Based on the available data, Genomically Directed Monotherapy was assigned a score of 2. This evaluation is based upon Phase 2 trial results which demonstrate some safety but lack efficacy evidence."
How many healthcare facilities in North America are offering this research trial?
"Participants of this medical trial are able to select from 29 sites located throughout the United States. While Gainesville, Washington and Anderson host clinical trials, there is likely a site near you that can minimize your travel requirements."
Share this study with friends
Copy Link
Messenger